After 100 days as FDA Commissioner, Dr. Marty Makary lays out his vision for reform, starting with the broken systems he’s uncovered inside the agency. He confronts the FDA’s failure in the opioid crisis, acknowledges the loss of public trust during COVID, and calls out regulatory capture and internal conflicts of interest, including practices that allowed FDA staff to block their own drug safety reviews. Makary announces a new policy to publish drug rejection letters and introduces a priority

Tag-uri: Coronavirus